Teratogenic Pierre Robin syndrome

Teratogenic Pierre Robin syndrome (Orphanet code 138059) is a rare congenital condition in which the characteristic features of Pierre Robin sequence — micrognathia (abnormally small lower jaw), glossoptosis (posterior displacement or retraction of the tongue), and often a cleft palate — arise as a result of prenatal exposure to a teratogenic agent rather than from a primary genetic cause. Teratogenic agents that have been implicated include certain medications, most notably methotrexate, alcohol, and other substances that can disrupt normal craniofacial development during embryogenesis. The condition primarily affects the craniofacial system. The underdeveloped mandible leads to posterior positioning of the tongue, which can obstruct the upper airway and cause significant breathing difficulties, particularly in the neonatal period. Feeding difficulties are also common due to the combination of the small jaw, tongue displacement, and cleft palate. In severe cases, airway obstruction can be life-threatening and may require urgent intervention. Additional anomalies may be present depending on the specific teratogenic exposure and its timing during fetal development. Management is primarily supportive and symptomatic. Airway management is the first priority and may range from prone positioning and nasopharyngeal airway placement to more invasive interventions such as mandibular distraction osteogenesis or, in severe cases, tracheostomy. Feeding support, including specialized bottles or nasogastric tube feeding, is often necessary. Cleft palate repair is typically performed surgically during infancy. Long-term follow-up with a multidisciplinary team including craniofacial surgeons, otolaryngologists, speech therapists, and geneticists is recommended to monitor growth, development, and any associated anomalies.

Common questions about Teratogenic Pierre Robin syndrome